{"locale":"en-DE","entries":{"k1046dwv8a5d":"Screenings","k10oos9tiuyy":"Mobile navigation","k1189az8godr":"Research","k12apkjn94py":"CGRP","k12blg3swkv":"HEALTH PRIME","k14yi1c7tt6f":"Executive Medical Office (for companies)","k150ze8r2mwk":"Many people do not even know they have glaucoma","k168ujy46k1l":"Home","k16b7hwq5o8h":"Bowel cancer screening","k17rvkludqok":"Terms and conditions","k186m5d07tlo":"Thyroid ultrasound","k189txcypybq":"Vo P, et al.: Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia 2018 Sep 19: 333102418801579.","k18vy5sdkc1m":"Close menu","k1a4epr0afn2":"Private Medical Office","k1alnq1cx6rl":"Get in touch","k1cujigjpl08":"Back to home","k1fh2lbau5h7":"Melanoma screening","k1fstccyxsb0":"Introducing a health programme","k1gcev2y8aab":"Further reading:","k1hiv2onsxg7":"Source: German Pain Congress, 17-20 October 2018, Mannheim (Germany)","k1ic2p4v0jc1":"Do sports medicine check-ups help?","k1il8w5iiddm":"© 2013 - 2026 Health Prime AG","k1itj9gtenpj":"Germany","k1k2nkszxhk1":"A dementia diagnosis should not be made lightly. Among the people around the patient, it provokes about as strong a reaction as a cancer diagnosis. And yet it is important,…","k1l5idq63wa4":"Vein screening","k1lb2r8jv2pq":"Skip to content","k1ltgixz2nlx":"Contents","k1n927q29qg6":"Legal notice","k1o3l5b28s6h":"Previous migraine prophylaxis: the dose makes the poison","k1oly4kh2add":"Service navigation","k1pims7t7ppa":"Genetic Sciences overview","k1q9lkcblsq1":"Two fewer headache days a month and a reduction in triptan use","k1r3bdtngicz":"The criteria for chronic migraine are met if a patient suffers from headaches on at least 15 days a month, and reports migraine-type headache on at least eight of those days. In episodic migraine, by contrast, sufferers have migraine on up to 14 days a month, at intervals of varying length.","k1toapcsnpjw":"All screenings","k1u1kl748inx":"More articles","k1v2cswpv11h":"Request a tailored quote for your company straight away.","k1vb56xzb8n7":"There is a need for better information and public education about this condition. In industrialised countries, the proportion of undiagnosed cases is estimated at…","k1w6dyfocbgd":"Company","k1waf48nc054":"Services","k1wubzd3wh2n":"Medical Family Office","k1xwy3sb3t2l":"Open menu","k1yc1erqtt4b":"New screenings for 2026","k1ytv0nl9x6c":"Medical Family Office submenu","k1zbw7km3f8x":"Nutrition coaching","k201dihoypwf":"Facts & Figures submenu","k202qpgmiygh":"More facts on workplace health","k22ck69h0ovy":"Fit for the future: modern migraine prophylaxis - Health Prime","k23nlqpuy8ej":"Pharmacogenetics","k241qhc3g5q1":"Screenings submenu","k24emjk4z7o1":"News","k26vaec5kyd5":"Preventive care","k29rd491eefi":"Main navigation","k2a6vommqew5":"CGRP is a strong vasodilator and plays a central role in triggering pain and in neurogenic inflammation. This insight led to an entirely new class of substances,…","k2ax55vf5lnu":"Current prophylactic therapies were originally developed for other indications and are often associated with poor tolerability and/or insufficient efficacy, said the speaker. Beta blockers are effective in reducing migraine attacks. However, this requires high doses, around 160 mg of propranolol. 'Which patient tolerates 160 mg of propranolol?', the speaker asked provocatively. Erectile dysfunction, low blood pressure and fatigue are common at this dose. The same applies to the anticonvulsant topiramate, an alternative to beta blockers in migraine prevention. With topiramate, a dose of up to 200 mg a day is needed. At this dose, undesirable effects are often to be expected, including paraesthesia, drowsiness, insomnia, difficulty concentrating and memory problems. The usual dose prescribed in the Charité migraine outpatient clinic is 50 mg; at this dose, the efficacy of topiramate is only just above placebo.","k2axbqyg8dqz":"WhatsApp Chat","k2bj88x3idbn":"Topics","k2d363kf5u0x":"Questions about screenings?","k2dn71huzv7t":"Dementia: early diagnosis matters","k2fs4t4vht26":"Pay attention to the number needed to harm","k2k573c6hhb":"About us","k4b1o0v1tsz":"Eye screening","k65vpw92kcd":"Epigenetic coaching","k68drlgk2t6":"In the prophylaxis of chronic migraine, botulinum toxin A has become established (in Germany). It is injected at a dose of 155 or 185 IU every three to four months into the forehead, temples, back of the head, neck and shoulder muscles.","k8cxwfzuh3o":"Genetic Sciences submenu","k8jd4zc9s6h":"Dr. med. Anka Stegmeier-Petroianu","kaiywayie5l":"Genetic Sciences","kbffimw9mjo":"'The probability of helping a migraine patient (chronic or episodic migraine) with erenumab is very high,' said Prof. Reuter, pointing to a study just published in the journal Cephalalgia [1]. It is substantially higher than with the prophylactics used until now. In addition, the number needed to harm, that is, the number of treated patients needed to produce one side effect, is at placebo level with erenumab, 13 with topiramate and 39 with botulinum toxin.","kbhxcesl9y":"Triptans, which are used in the treatment of migraine, also inhibit the release of CGRP, among other things, by acting as agonists at 5-HT1 receptors. As is well known, migraine is not just a matter of headaches. Patients often feel nauseous, lose their appetite, have visual disturbances and become hypersensitive to light and noise. These symptoms are also associated with a considerable impairment of quality of life. According to Prof. Dr. med. Uwe Reuter of Charité Berlin, speaking at the German Pain Congress, it is all the more important to be able to offer these chronic patients a well-tolerated prophylaxis with few side effects. The aim of drug prophylaxis, he added, is not only to reduce the frequency, severity and duration of migraine attacks, but also to curb triptan use and other painkiller consumption, and to prevent the medication-overuse headache that can develop as painkiller consumption rises.","kcx14z5lns4":"The choice of drug for migraine prophylaxis depends on its efficacy on the one hand and, on the other, on its tolerability and how likely it is to cause side effects.","kdps33hei9g":"The business case for corporate health management","kdwfu4nq3vu":"In summary, there would be no reason (other than financial) to withhold the new prophylaxis from migraine patients, said Prof. Reuter.","ke0k1i32uuh":"CGRP is a strong vasodilator and plays a central role in triggering pain and in neurogenic inflammation. This insight led to an entirely new class of substances, which represents a quantum leap in migraine prophylaxis compared with the options available until now.","keqq86u2g4g":"Reuter U, et al.: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018 Oct 22. DOI: 10.1016/S0140-6736(18)32534-0 [Epub ahead of print].","kersts0hxf2":"Migraine","kh3eli3ase2":"Contact","kh42f23d590":"Countries","khh2avjgz3h":"Headaches","khse1h7mahq":"Fit for the future: modern migraine prophylaxis","kimyd3rdqlw":"WhatsApp","kiq30e5j53t":"References","kj5472kr8vh":"You are here","kj5hqx0025b":"Clients","kj7l8xbhfqh":"Health promotion, mental health and stress management for your employees through corporate health management. We combine innovative pharmacogenetics with practical health solutions.","kksz2b1dw7h":"Private Medical Office (for individuals)","klpk5vjovr5":"Samstagernstrasse 55","kmfe0csajlf":"info@health-prime.ch","kmk6jpiurug":"Corporate health management in figures: Switzerland 2026","kmkd7bm6s4o":"Workshops and seminars","kokce5pld6q":"Data security","kow7sqvye5g":"Facts & Figures","kp2jsof3d7c":"Cardiovascular screening","kqyz70bwgoq":"Executive Medical Office","kr1u7k9xyg3":"No direct comparison of efficacy between the three substances is available; studies are hardly comparable because of differences in study design and duration. All three monoclonal antibodies are more effective than placebo and, in indirect comparison, as effective as the migraine prophylactics used until now.","kr5cyt7qe9h":"Corporate health management in figures: Germany 2026","kssutum3jvy":"Menu","kt627t5jiqi":"Switzerland","ktx8sa9l6w8":"Legal","kulwamvak4j":"Reducing chronic and episodic migraine","kv6e2aavawz":"Health Prime AG","kwfljv9snhe":"The sudden cardiac death of an apparently healthy athlete is shocking. Despite its low incidence, work is under way on ways of detecting SCD early. Among…","kxsj3gutdp6":"Language","kyjg92veavd":"8832 Wollerau","kymf1hv6jp6":"Data protection in corporate health management","kz9aj5pitq5":"Three CGRP antibodies were shown in studies to be more effective than placebo and to lead to a significant reduction in migraine days. All three substances produce a significant therapeutic effect within the first four weeks of treatment, and are also well tolerated. Their side-effect profile is at placebo level, with the exception of reactions at the injection site. Specifically, these are erenumab, a CGRP receptor-binding antibody already approved on the European market for the prophylaxis of migraine in adults, the antibody galcanezumab, and the monoclonal antibody fremanezumab, which can be given quarterly or monthly. Two of the substances, galcanezumab and fremanezumab, target CGRP directly, while erenumab docks onto the CGRP receptor and blocks it.","kzs43xb30bo":"Health","m12wi4997s6j":"<0>Preventive care</0>","m14gnjwlnbmx":"<0>Private Medical Office (for individuals)</0>","m15sej786j64":"<0>Executive Medical Office (for companies)</0>","m17fz3yk31p8":"<0>Bowel cancer screening</0>","m17hjtpobn6t":"<0/><1>Email</1>","m1cmstfk1tsp":"<0>Legal notice</0>","m1ctqemcewl0":"<0>Cardiovascular screening</0>","m1d6cgdocia1":"<0>Switzerland</0>","m1d7hygejiy3":"<0>Clients</0>","m1exjztmyco5":"<0>Introducing a health programme</0>","m1hdooaqgbhc":"<0>Source: German Pain Congress, 17-20 October 2018, Mannheim (Germany)</0>","m1hlda79j9tu":"<0>CGRP is a strong vasodilator and plays a central role in triggering pain and in neurogenic inflammation. This insight led to an entirely new class of substances, which represents a quantum leap in migraine prophylaxis compared with the options available until now.</0>","m1in2dglzpir":"<0>Genetic Sciences overview</0>","m1lgk2dt2owg":"<0>Headaches</0>","m1nfkdxmujpp":"<0>Home</0>","m1oaji6gkxjg":"<0>Nutrition coaching</0>","m1of8iky5op3":"<0><1/><2>WhatsApp</2></0><3><4/><5>Email</5></3><6><7/><8>Phone</8></6>","m1ou2d2zwh98":"<0>Dementia: early diagnosis matters</0>","m1p2cgpi6ovw":"<0>Melanoma screening</0>","m1r643hoenid":"<0>Data security</0>","m1syz9m45ip5":"With botulinum toxin A, headache days fall by eight days a month, compared with six days with placebo. The net benefit is therefore two days a month. In studies of patients with episodic migraine and an average of eight migraine days a month, treatment with erenumab brought a reduction<0/> of about three days. The monoclonal antibody erenumab also reduces headache days in patients who have not responded to other prophylactics.","m1txtefb6e57":"<0>Pay attention to the number needed to harm</0>","m1ugfbp2oaoi":"<0>Germany</0>","m1utmwqn663u":"<0/><1>Telephone</1>","m1xtadap1hcg":"<0>Eye screening</0>","m1y4hepzxvtm":"<0>Health</0>","m1z4yqvjr62m":"<0>Epigenetic coaching</0>","m208u7fvykda":"<0>Fit for the future: modern migraine prophylaxis</0>","m21k72mwzlxb":"<0>The business case for corporate health management</0>","m226ya896wxe":"<0>Do sports medicine check-ups help?</0>","m2bi32pekmp":"<0>All screenings</0>","m2chs8dveg50":"<0>Pharmacogenetics</0>","m2fjb4do50kz":"<0>References</0>","m2fqen7cvbcp":"<0>Reducing chronic and episodic migraine</0>","m2gjynkfy3z5":"<0>Corporate health management in figures: Switzerland 2026</0>","m3qe3th86uq":"<0>Contact</0>","m50zqibw1tj":"<0>Previous migraine prophylaxis: the dose makes the poison</0>","m6frqg4nxit":"<0>Menu</0><1><2/></1>","m7q0kh4dtp8":"<0>Health Prime AG</0><1>Samstagernstrasse 55</1><2>8832 Wollerau</2><3>info@health-prime.ch</3><4>+41 44 250 28 71</4><5>WhatsApp Chat</5>","m7s3c6mnozd":"<0>Data protection in corporate health management</0>","m9g5cpsqvhw":"<0>Terms and conditions</0>","mbavhnixqou":"<0>Migraine</0>","mdgj0lfonq6":"<0>New screenings for 2026</0>","mlhhref2ups":"<0>About us</0>","mmgtv9g0a5v":"<0>Workshops and seminars</0>","mr78eemfrr4":"<0>Two fewer headache days a month and a reduction in triptan use</0>","mrkpaibzy3a":"<0>Vein screening</0>","ms778pbbufy":"<0>Table 1</0> shows drug prophylaxis for migraine.","mts9dotk3y8":"<0>Many people do not even know they have glaucoma</0>","mwtbnhfjbma":"<0>Contact</0><1><2/></1>","mxikjjcp0vb":"<0>Thyroid ultrasound</0>","myjbghtnpj1":"<0><1/><2><3>More articles</3><4><5/><6/><7/></4></2></0>","mzzpsn65wfb":"<0>Research</0>","t1fzvydj1vxj":"+{0} {1} {2} {3} {4}"}}